Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CureVac ( (CVAC) ) has shared an announcement.
On June 12, 2025, CureVac N.V. entered into a purchase agreement with BioNTech SE, under which BioNTech will acquire CureVac through a public exchange offer. This acquisition will lead to CureVac’s delisting from Nasdaq and its transformation into a privately held entity. The agreement stipulates a series of reorganization steps, including a Dutch legal downstream merger, to ensure BioNTech becomes the sole owner of CureVac’s operations. The transaction is subject to regulatory approvals and shareholder consent, with implications for CureVac’s market presence and strategic direction.
The most recent analyst rating on (CVAC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.
Spark’s Take on CVAC Stock
According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.
CureVac demonstrates strong financial and technical performance, with significant improvements in revenue and profitability, and a robust technical setup. The strategic partnership with GSK and progress in oncology and patent validation are positives. However, overbought technical indicators and restructuring challenges pose risks.
To see Spark’s full report on CVAC stock, click here.
More about CureVac
CureVac N.V. is a biotechnology company based in Tübingen, Germany, specializing in the development of mRNA-based therapies and vaccines. The company focuses on advancing its proprietary RNA technology platform to develop treatments for various diseases, including cancer and infectious diseases.
Average Trading Volume: 1,083,047
Technical Sentiment Signal: Buy
Current Market Cap: $1.25B
For a thorough assessment of CVAC stock, go to TipRanks’ Stock Analysis page.